ATX Stock Overview
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Amplia Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.064 |
| 52 Week High | AU$0.12 |
| 52 Week Low | AU$0.06 |
| Beta | 0.52 |
| 1 Month Change | -16.88% |
| 3 Month Change | -20.00% |
| 1 Year Change | -35.35% |
| 3 Year Change | -76.73% |
| 5 Year Change | -46.67% |
| Change since IPO | -96.80% |
Recent News & Updates
Recent updates
We Think Amplia Therapeutics (ASX:ATX) Needs To Drive Business Growth Carefully
Jan 13
Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Apr 28Amplia Therapeutics Limited (ASX:ATX) Insiders Increased Their Holdings
Feb 28Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth
Jan 06
Shareholder Returns
| ATX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 4.9% | 1.9% | 0.9% |
| 1Y | -35.4% | -7.7% | 5.6% |
Return vs Industry: ATX underperformed the Australian Biotechs industry which returned -7.7% over the past year.
Return vs Market: ATX underperformed the Australian Market which returned 5.6% over the past year.
Price Volatility
| ATX volatility | |
|---|---|
| ATX Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: ATX's share price has been volatile over the past 3 months.
Volatility Over Time: ATX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Chris Burns | www.ampliatx.com |
Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company’s product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other solid tumors and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for acute myeloid leukemia (AML) and certain solid tumors It has a collaboration agreement with the Garvan Institute of Media Research in Sydney.
Amplia Therapeutics Limited Fundamentals Summary
| ATX fundamental statistics | |
|---|---|
| Market cap | AU$11.64m |
| Earnings (TTM) | -AU$4.46m |
| Revenue (TTM) | AU$1.87m |
6.6x
P/S Ratio-2.8x
P/E RatioIs ATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATX income statement (TTM) | |
|---|---|
| Revenue | AU$1.87m |
| Cost of Revenue | AU$371.98k |
| Gross Profit | AU$1.50m |
| Other Expenses | AU$5.96m |
| Earnings | -AU$4.46m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.023 |
| Gross Margin | 80.09% |
| Net Profit Margin | -238.69% |
| Debt/Equity Ratio | 14.3% |
How did ATX perform over the long term?
See historical performance and comparison